ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Emmanuel S. Antonarakis, Sumit Kumar Subudhi, Christopher Michael Pieczonka, Lawrence Ivan Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew D. Harmon, Nadeem Anwar Sheikh, Neal D. Shore, Daniel Peter Petrylak

Open full text 0 citations

Abstract

Supplementary Data for Antonarakis et al

Open-access reader

About this research paper

What this paper is about

Supplementary Data for Antonarakis et al

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Supplementary Data for Antonarakis et al

Key concepts: Enzalutamide, Abiraterone acetate, Prostate cancer, Medicine, Abiraterone, STRIDE, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials — Research Paper | ScholarLens